Business Wire

ProDERM Study Results of octagam ® 10% Treatment in Patients With Dermatomyositis Published in the New England Journal of Medicine

Share

Octapharma announced today the results from the ProDERM study on the efficacy and safety of octagam® 10% [Immune Globulin Intravenous (Human)], in adult dermatomyositis (DM) patients have been published in the New England Journal of Medicine (Aggarwal R et al. “Efficacy and safety of intravenous immunoglobulin in dermatomyositis”).

Dermatomyositis is an immune-mediated myopathy characterised by chronic inflammation of the skin and muscles, leading to cutaneous rashes and progressive muscle weakness. DM is associated with increased morbidity and mortality due to muscle weakness and visceral involvement. Prior to the ProDERM study findings, no therapy had been approved in the US or Europe for the treatment of dermatomyositis based on randomized clinical trials.

The Progress in DERMatomyositis (ProDERM) study was the first large randomized clinical trial to investigate an intravenous immunoglobulin (IVIg) (octagam® 10%) in dermatomyositis. The results of the study demonstrated that octagam® 10% is an efficacious and well-tolerated treatment for adults with dermatomyositis. The study enrolled 95 adults from 36 sites in 10 countries and reported the following key findings:

  • The primary endpoint of the ProDERM study was met, with a significantly higher proportion of responders in the octagam® 10% group compared with the placebo group (79% vs. 44%; p <0.001) at Week 16 (end of the double-blind, placebo-controlled period).
  • Significantly more patients receiving octagam® 10% achieved a major or at least moderate improvement in the Total Improvement Score.
  • The efficacy of octagam® 10% was maintained through Week 40 (the end of the open-label extension period).
  • octagam® 10% was generally well tolerated. The safety and tolerability profile of IVIg was consistent with previously reported safety outcomes for IVIg administration.

“The lack of treatment options for dermatomyositis has hampered patient care to date,” said Rohit Aggarwal, MD, MS, Medical Director of the Arthritis and Autoimmunity Center at the University of Pittsburgh School of Medicine and chair of the ProDERM study Steering Committee. “The ProDERM study – and its publication in the New England Journal of Medicine – has been a clear turning point in the management of patients with this disease, with physicians now able to offer patients an effective treatment option with proven efficacy, safety and tolerability.” Wolfgang Frenzel, MD, Board Member and Head of Research and Development at Octapharma added, “We are very proud that octagam® 10% is the first product to demonstrate efficacy in a large, randomized controlled trial in dermatomyositis.”

“The ProDERM trial has given clinicians much more confidence in the efficacy and safety of octagam® 10% for adult DM patients,” said Octapharma USA President Flemming Nielsen. "The New England Journal of Medicine journal article is an exciting milestone for both providers and patients who previously relied on unapproved treatments for the disorder. We look forward to partnering with patient organizations and the medical community to develop educational and other support programs that will serve dermatomyositis patients.”

Early diagnosis and treatment are important for optimal management of patients with dermatomyositis, but diagnosis can be very challenging. “At Octapharma, we are committed to improving early detection and management of this rare disease,” said Olaf Walter, MD, MBA, Board Member and Head of International Business Units (IBUs) at Octapharma. “Our activities include the launch of a disease awareness website for healthcare practitioners (www.managedermatomyositis.com) and participation in congresses, such as the upcoming ACR (American College of Rheumatology) Convergence, taking place in November in Philadelphia, where the latest advances on this disorder are being shared.”

Following the results of the ProDERM study, octagam® 10% has received approval in the US for the “treatment of dermatomyositis in adults”and in Europe for “immunomodulation in adults with active dermatomyositis treated with immunosuppressive drugs including corticosteroids, or with intolerance or contra-indications to those drugs.”

About the ProDERM study

The ProDERM study (NCT02728752) was an international, multicenter, double-blind, randomized, placebo-controlled phase III clinical trial that investigated the efficacy, safety and tolerability of octagam® 10% in adults with dermatomyositis. In the initial 16-week placebo-controlled period, 95 patients from 36 sites in 10 countries were randomized to receive either octagam® 10% (2.0 g/kg) or placebo every four weeks. This was followed by an open-label extension period during which all patients received octagam® 10% for a further 24 weeks (excluding patients who had shown clinical worsening while receiving octagam® 10% in the first period). The primary endpoint was the proportion of patients who responded to treatment at Week 16.

About octagam®

octagam® 10% is a ready to use, liquid preparation of highly purified human immunoglobulin for intravenous administration. octagam® 10% is approved for idiopathic thrombocytopenic purpura in the USA, EU and Canada. It is also approved for use in treatment of primary immunodeficiency, secondary immunodeficiencies and Guillain Barré syndrome in the EU and Canada, for dermatomyositis in the EU and the USA, and for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN), and Kawasaki disease in the EU.

FOR THE US:

WARNING

THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURE

Thrombosis may occur with immune globulin intravenous (IGIV) products, including octagam® 10%. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur with the administration of immune globulin intravenous (Human) (IGIV) products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. octagam® 10% does not contain sucrose. For patients at risk of thrombosis, renal dysfunction or renal failure, administer octagam® 10% at the minimum infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

For full prescribing information, including complete boxed warning, please click here. To learn more about octagam® 10% for the treatment of dermatomyositis, please click here.

About Octapharma

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines.

Octapharma employs more than 10,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: immunotherapy, hematology, and critical care.

Octapharma has seven R&D sites and five state-of-the-art manufacturing facilities in Austria, France, Germany and Sweden, and operates more than 180 plasma donation centers across Europe and the US.

The company’s American subsidiary, Octapharma USA, is located in Paramus, N.J. Octapharma operates three state-of-the-art production sites licensed by the U.S. Food and Drug Administration (FDA), providing a high level of production flexibility.

Website: www.octapharma.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Octapharma AG
Ivana Spotakova, Communications Manager
ivana.spotakova@octapharma.com, Tel.: +41793474607

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NIKE, Inc. Board of Directors Announces Long-Time Nike Veteran Elliott Hill to Return as President and Chief Executive Officer John Donahoe to Retire from Nike19.9.2024 22:15:00 CEST | Press release

The Board of Directors of NIKE, Inc. (NYSE:NKE) announced today that Elliott Hill will become President and Chief Executive Officer of NIKE, Inc., effective October 14, 2024. Hill will also become a Director of the NIKE, Inc. Board of Directors and a member of the Executive Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240919388699/en/ Incoming NIKE, Inc. President & CEO Elliott Hill (Photo: Business Wire) “I am excited to welcome Elliott back to NIKE. Given our needs for the future, the past performance of the business, and after conducting a thoughtful succession process, the Board concluded it was clear Elliott’s global expertise, leadership style, and deep understanding of our industry and partners, paired with his passion for sport, our brands, products, consumers, athletes, and employees, make him the right person to lead Nike’s next stage of growth,” said Mark Parker, Executive Chairman of NIKE, Inc. “Pers

Mary Kay Expands Into Kyrgyzstan, Further Elevating Beauty and Empowerment Around the World19.9.2024 19:03:00 CEST | Press release

Mary Kay Inc., a global leader in skin care and cosmetics, is proud to announce its expansion into Kyrgyzstan, marking a significant milestone in its ongoing international growth strategy. This exciting development underscores Mary Kay’s commitment to empowering women and providing innovative, high-quality skincare and beauty products across the globe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240919159057/en/ Mary Kay’s expansion into Kyrgyzstan marks another step forward in the company’s mission to enrich women’s lives around the world, offering top-tier beauty products and unparalleled business opportunities. (Photo: Mary Kay Inc.) The beauty and personal care market is experiencing robust growth internationally, with sales volume in these categories almost doubling over the past several years. The beauty market is expected to reach approximately $580 billion by 2027, growing by a projected 6 percent per year1 while

Xsolla Partners With AbleGamers for Charity Campaign at TwitchCon 202419.9.2024 19:00:00 CEST | Press release

Xsolla, a global video game commerce company, is excited to announce its collaboration with AbleGamers for an impactful charity campaign at TwitchCon 2024. This partnership aims to further AbleGamers' mission of improving accessibility in gaming for individuals with disabilities through an interactive and meaningful activation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240919722398/en/ (Graphic: Xsolla) Attendees who visit the Xsolla booth (Booth 1515-SW) at TwitchCon will have the exclusive opportunity to claim one of two specially designed charity pins. By sharing a photo of their pin on their social channels on Instagram, Facebook, or Twitter using the hashtags #LightstreamAble and #XsollaAble, participants will help raise funds for AbleGamers. For every qualifying social post, Xsolla and its partners will donate $5 to AbleGamers, up to $10,000. To amplify awareness, include hashtags: #TwitchCon #BongoCat #Lightstrea

Sandvine Announces New Ownership and Capital Infusion19.9.2024 18:38:00 CEST | Press release

Sandvine (the “Company”), a market-leading provider of Over-the-Top (OTT) Application Classification and Quality of Experience (QoE) solutions, today announced that it has been acquired by a group of leading US investment firms that previously were, and continue to be, lenders to the Company. In connection with this change of control transaction, the lenders agreed to reduce the Company’s total outstanding debt significantly. Following the change of control transaction, on September 13, 2024, these investors also entered into a binding agreement to provide new capital to Sandvine. The financing is expected to close in September 2024 and will strengthen the Company’s balance sheet. These enhancements to Sandvine’s financial position accompany its recently announced reorientation of its business model to focus on serving customers in large democratic markets. Together, these developments enable the Company to continue serving as the technology partner of choice for scaled, sophisticated

Neuraptive Therapeutics Announces Presentation of Phase 2 Topline Interim Results for NTX-001 at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting19.9.2024 18:31:00 CEST | Press release

Neuraptive Therapeutics Inc., a leading biopharmaceutical company focused on novel treatments for peripheral nerve injuries, today announced that interim topline results from its ongoing Phase 2 NEUROFUSE Study will be presented at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting, held September 19-21 in Minneapolis, MN. The presentation, titled Safety and Efficacy of NTX-001 in the Treatment of Acute Single Transected Peripheral Nerve Injuries: A Phase 2 Randomized Controlled Trial, was awarded a Top 10 Best Paper designation and will be presented by Dr. David Brogan of Washington University during the scientific paper session on Thursday, September 19. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240919597699/en/ David M. Brogan, MD, MSc, Assistant Professor, Orthopaedic Surgery, Division of Hand and Microsurgery, Washington University in St. Louis (Photo: Business Wire) The presentation will highl

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye